Tau antibody 77G7 targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation

Introduction Neurofibrillary tangle (NFT) of hyperphosphorylated tau is a hallmark of Alzheimer's disease (AD) and related tauopathies. Tau lesion starts in the trans‐entorhinal cortex, from where it spreads to limbic regions, followed by neocortical areas. The regional distribution of NFTs associates with the progression of AD. Accumulating evidence suggests that proteopathic tau can seed tau aggregation in a prion‐like fashion in vitro and in vivo. Inhibition of tau seeding activity could provide a potential therapeutic opportunity to block the propagation of tau pathology in AD and related tauopathies. Aims In the present study, we investigated the role of 77G7, a monoclonal tau antibody to the microtubule‐binding repeats, in repressing the seeding activity of proteopathic tau. Results We found that 77G7 had a higher affinity toward aggregated pathological tau fractions than un‐aggregated tau derived from AD brain. 77G7 inhibited the internalization of tau aggregates by cells, blocked AD O‐tau to capture normal tau, and to seed tau aggregation in vitro and in cultured cells. Tau pathology induced by hippocampal injection of AD O‐tau in 3xTg‐AD mice was suppressed by mixing 77G7 with AD O‐tau. Intravenous administration of 77G7 ameliorated site‐specific hyperphosphorylation of tau induced by AD O‐tau in the hippocampi of Tg/hTau mice. Conclusion These findings indicate that 77G7 can effectively suppress the seeding activity of AD O‐tau and thus could be developed as a potential immunotherapeutic drug to inhibit the propagation of tau pathology in AD and related tauopathies. Tau monoclonal antibody 77G7 targets microtubule binding repeats of tau. 77G7 displayed a higher affinity toward pathological tau. 77G7 inhibited the internalization of tau aggregates by cells, blocked oligomeric tau derived from AD brain to capture normal tau and to seed tau aggregation in vitro, in cultured cells and in vivo. Thus, 77G7 could be developed as a potential immunotherapeutic drug to inhibit the propagation of tau pathology in AD and related tauopathies.